Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Before and After Photoshop: Recursive Fraud in the Age of Digital Reproducibility.

Biagioli M.

Angew Chem Int Ed Engl. 2019 Sep 30. doi: 10.1002/anie.201908646. [Epub ahead of print]

PMID:
31568606
2.

The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions.

Biagioli M, Carino A, Fiorucci C, Annunziato G, Marchianò S, Bordoni M, Roselli R, Giorgio CD, Castiglione F, Ricci P, Bruno A, Faccini A, Distrutti E, Baldoni M, Costantino G, Fiorucci S.

Nutrients. 2019 Aug 7;11(8). pii: E1820. doi: 10.3390/nu11081820.

3.

Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.

Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1422-1437. doi: 10.1016/j.bbalip.2019.07.006. Epub 2019 Jul 17.

PMID:
31325638
4.

Biological Indices Evaluation of Various Treatment Techniques for Left-Sided Breast Treatment.

Saini AS, Das IJ, Hwang CS, Biagioli MC, Lee WE 3rd.

Pract Radiat Oncol. 2019 Jul 5. pii: S1879-8500(19)30192-4. doi: 10.1016/j.prro.2019.06.020. [Epub ahead of print]

PMID:
31283990
5.

GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis.

Biagioli M, Carino A, Fiorucci C, Marchianò S, Di Giorgio C, Roselli R, Magro M, Distrutti E, Bereshchenko O, Scarpelli P, Zampella A, Fiorucci S.

Cell Mol Gastroenterol Hepatol. 2019 Jun 18;8(3):447-473. doi: 10.1016/j.jcmgh.2019.06.003. [Epub ahead of print]

6.

Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity.

Biagioli M, Carino A.

Handb Exp Pharmacol. 2019;256:95-108. doi: 10.1007/164_2019_225. Review.

PMID:
31119464
7.

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.

Carino A, Marchianò S, Biagioli M, Fiorucci C, Zampella A, Monti MC, Morretta E, Bordoni M, Di Giorgio C, Roselli R, Ricci P, Distrutti E, Fiorucci S.

Nutrients. 2019 May 21;11(5). pii: E1132. doi: 10.3390/nu11051132.

8.

Incorporating Routine Magnetic Resonance Imaging-based Planning for the Delivery of High-dose-rate Brachytherapy for Prostate Cancer: An Evaluation of Clinical Feasibility and Dosimetric Outcomes.

Saigal K, All S, Potrebko P, Feranec N, Keller A, Lizaso M, Warner C, Nguyen N, Jain A, Biagioli M.

Cureus. 2019 Feb 16;11(2):e4085. doi: 10.7759/cureus.4085.

9.

Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.

Sepe V, Marchianò S, Finamore C, Baronissi G, Di Leva FS, Carino A, Biagioli M, Fiorucci C, Cassiano C, Monti MC, Del Gaudio F, Novellino E, Limongelli V, Fiorucci S, Zampella A.

ACS Med Chem Lett. 2018 Dec 6;10(4):407-412. doi: 10.1021/acsmedchemlett.8b00423. eCollection 2019 Apr 11.

PMID:
30996771
10.

Hypomorphic mutation of the mouse Huntington's disease gene orthologue.

Murthy V, Tebaldi T, Yoshida T, Erdin S, Calzonetti T, Vijayvargia R, Tripathi T, Kerschbamer E, Seong IS, Quattrone A, Talkowski ME, Gusella JF, Georgopoulos K, MacDonald ME, Biagioli M.

PLoS Genet. 2019 Mar 21;15(3):e1007765. doi: 10.1371/journal.pgen.1007765. eCollection 2019 Mar.

11.

Weighing intellectual property: Can we balance the social costs and benefits of patenting?

Biagioli M.

Hist Sci. 2019 Mar;57(1):140-163. doi: 10.1177/0073275318797787. Epub 2018 Oct 22.

PMID:
30880495
12.

Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties.

Biagioli M, Capobianco D, Carino A, Marchianò S, Fiorucci C, Ricci P, Distrutti E, Fiorucci S.

Nutrients. 2019 Feb 2;11(2). pii: E325. doi: 10.3390/nu11020325.

13.

"Technologies of the law/ law as a technology".

Biagioli M, Buning M.

Hist Sci. 2019 Mar;57(1):3-17. doi: 10.1177/0073275318816163. Epub 2018 Dec 21.

PMID:
30574798
14.

Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis.

Carino A, Marchianò S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, Fiorucci C, Zampella A, Monti MC, Distrutti E, Fiorucci S.

FASEB J. 2019 Feb;33(2):2809-2822. doi: 10.1096/fj.201801373RR. Epub 2018 Oct 10.

PMID:
30303744
15.

GammaKnife versus VMAT radiosurgery plan quality for many brain metastases.

Potrebko PS, Keller A, All S, Sejpal S, Pepe J, Saigal K, Kandula S, Sensakovic WF, Shridhar R, Poleszczuk J, Biagioli M.

J Appl Clin Med Phys. 2018 Nov;19(6):159-165. doi: 10.1002/acm2.12471. Epub 2018 Oct 4.

16.

Bile Acids Activated Receptors Regulate Innate Immunity.

Fiorucci S, Biagioli M, Zampella A, Distrutti E.

Front Immunol. 2018 Aug 13;9:1853. doi: 10.3389/fimmu.2018.01853. eCollection 2018. Review.

17.

Future trends in the treatment of non-alcoholic steatohepatitis.

Fiorucci S, Biagioli M, Distrutti E.

Pharmacol Res. 2018 Aug;134:289-298. doi: 10.1016/j.phrs.2018.07.014. Epub 2018 Jul 17. Review.

PMID:
30021122
18.

SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: Application to treatment response.

Potrebko PS, Shridhar R, Biagioli MC, Sensakovic WF, Andl G, Poleszczuk J, Fox TH.

J Appl Clin Med Phys. 2018 Sep;19(5):435-443. doi: 10.1002/acm2.12400. Epub 2018 Jul 1.

19.

Evaluation of sparing organs at risk (OARs) in left-breast irradiation in the supine and prone positions and with deep inspiration breath-hold.

Saini AS, Hwang CS, Biagioli MC, Das IJ.

J Appl Clin Med Phys. 2018 Jul;19(4):195-204. doi: 10.1002/acm2.12382. Epub 2018 Jun 21.

20.

Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.

Fiorucci S, Biagioli M, Distrutti E.

Dig Dis Sci. 2018 Sep;63(9):2168-2171. doi: 10.1007/s10620-018-5039-y. No abstract available.

PMID:
29611077
21.

Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.

Carino A, Biagioli M, Marchianò S, Scarpelli P, Zampella A, Limongelli V, Fiorucci S.

Pharmacol Res. 2018 May;131:17-31. doi: 10.1016/j.phrs.2018.02.033. Epub 2018 Mar 9.

PMID:
29530598
22.

Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes.

Altazi BA, Fernandez DC, Zhang GG, Hawkins S, Naqvi SM, Kim Y, Hunt D, Latifi K, Biagioli M, Venkat P, Moros EG.

Phys Med. 2018 Feb;46:180-188. doi: 10.1016/j.ejmp.2017.10.009. Epub 2018 Feb 21.

PMID:
29475772
23.

The Unexpected Tuners: Are LncRNAs Regulating Host Translation during Infections?

Knap P, Tebaldi T, Di Leva F, Biagioli M, Dalla Serra M, Viero G.

Toxins (Basel). 2017 Nov 3;9(11). pii: E357. doi: 10.3390/toxins9110357.

24.

Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.

Biagioli M, Mencarelli A, Carino A, Cipriani S, Marchianò S, Fiorucci C, Donini A, Graziosi L, Baldelli F, Distrutti E, Costantino G, Fiorucci S.

Inflamm Bowel Dis. 2017 Dec 19;24(1):123-135. doi: 10.1093/ibd/izx031.

PMID:
29272492
25.

Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice.

Carino A, Cipriani S, Marchianò S, Biagioli M, Scarpelli P, Zampella A, Monti MC, Fiorucci S.

Sci Rep. 2017 Oct 20;7(1):13689. doi: 10.1038/s41598-017-13102-y.

26.

Wnt/β-Catenin Signaling Induces Integrin α4β1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice.

Sorcini D, Bruscoli S, Frammartino T, Cimino M, Mazzon E, Galuppo M, Bramanti P, Al-Banchaabouchi M, Farley D, Ermakova O, Britanova O, Izraelson M, Chudakov D, Biagioli M, Sportoletti P, Flamini S, Raspa M, Scavizzi F, Nerlov C, Migliorati G, Riccardi C, Bereshchenko O.

J Immunol. 2017 Nov 1;199(9):3031-3041. doi: 10.4049/jimmunol.1700247. Epub 2017 Sep 22.

27.

Reproducibility of F18-FDG PET radiomic features for different cervical tumor segmentation methods, gray-level discretization, and reconstruction algorithms.

Altazi BA, Zhang GG, Fernandez DC, Montejo ME, Hunt D, Werner J, Biagioli MC, Moros EG.

J Appl Clin Med Phys. 2017 Nov;18(6):32-48. doi: 10.1002/acm2.12170. Epub 2017 Sep 11.

28.

Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity.

Biagioli M, Laghi L, Carino A, Cipriani S, Distrutti E, Marchianò S, Parolin C, Scarpelli P, Vitali B, Fiorucci S.

Front Pharmacol. 2017 Jul 28;8:505. doi: 10.3389/fphar.2017.00505. eCollection 2017.

29.

The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis.

Biagioli M, Carino A, Cipriani S, Francisci D, Marchianò S, Scarpelli P, Sorcini D, Zampella A, Fiorucci S.

J Immunol. 2017 Jul 15;199(2):718-733. doi: 10.4049/jimmunol.1700183. Epub 2017 Jun 12.

30.

Epigenetics of Huntington's Disease.

Bassi S, Tripathi T, Monziani A, Di Leva F, Biagioli M.

Adv Exp Med Biol. 2017;978:277-299. doi: 10.1007/978-3-319-53889-1_15. Review.

PMID:
28523552
31.

Investigating multi-objective fluence and beam orientation IMRT optimization.

Potrebko PS, Fiege J, Biagioli M, Poleszczuk J.

Phys Med Biol. 2017 Jul 7;62(13):5228-5244. doi: 10.1088/1361-6560/aa7298. Epub 2017 May 11.

PMID:
28493848
32.

Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.

Chung H, Polf J, Badiyan S, Biagioli M, Fernandez D, Latifi K, Wilder R, Mehta M, Chuong M.

J Appl Clin Med Phys. 2017 Jan;18(1):32-39. doi: 10.1002/acm2.12001. Epub 2016 Nov 21.

33.

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis.

Carino A, Cipriani S, Marchianò S, Biagioli M, Santorelli C, Donini A, Zampella A, Monti MC, Fiorucci S.

Sci Rep. 2017 Feb 16;7:42801. doi: 10.1038/srep42801.

34.

Role of Gamma Knife® Radiosurgery for the Treatment of Brain Metastases from Gynecological Cancers.

Keller A, Ismail R, Potrebko PS, Pepe J, Wu M, Saigal K, Biagioli M, Shridhar R, Holloway R, Field M, Rao NG.

Cureus. 2016 Dec 31;8(12):e947. doi: 10.7759/cureus.947.

35.

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.

Wahl AO, Gaffney DK, Jhingran A, Yashar CM, Biagioli M, Elshaikh MA, Jolly S, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Williams NL, Small W Jr.

Oncology (Williston Park). 2016 Sep 15;30(9):816-22. Review.

36.

Watch out for cheats in citation game.

Biagioli M.

Nature. 2016 Jul 14;535(7611):201. doi: 10.1038/535201a. No abstract available.

37.

ACR Appropriateness Criteria® Management of Recurrent Endometrial Cancer.

Elshaikh MA, Vance S, Gaffney DK, Biagioli M, Jhingran A, Jolly S, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Wahl AO, Williams NL, Yashar CM, Small W Jr; Expert Panel on Radiation Oncology–Gynecology:.

Am J Clin Oncol. 2016 Oct;39(5):507-15. doi: 10.1097/COC.0000000000000318.

PMID:
27400117
38.

Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.

Finamore C, Festa C, Renga B, Sepe V, Carino A, Masullo D, Biagioli M, Marchianò S, Capolupo A, Monti MC, Fiorucci S, Zampella A.

Sci Rep. 2016 Jul 6;6:29320. doi: 10.1038/srep29320.

39.

Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma.

Naghavi AO, Gonzalez RJ, Scott JG, Mullinax JE, Abuodeh YA, Kim Y, Binitie O, Ahmed KA, Bui MM, Saini AS, Zager JS, Biagioli MC, Letson D, Harrison LB, Fernandez DC.

Brachytherapy. 2016 Jul-Aug;15(4):495-503. doi: 10.1016/j.brachy.2016.03.013. Epub 2016 May 12.

PMID:
27180128
40.

Body mass index, fat free mass, uric acid, and renal function as blood pressure levels determinants in young adults.

Sidoti A, Nigrelli S, Rosati A, Bigazzi R, Caprioli R, Fanelli R, Acconcia P, Borracelli D, Biagioli M, Angelini D, Parrini M, Tonelli L, Tosi P, Manzoni D.

Nephrology (Carlton). 2017 Apr;22(4):279-285. doi: 10.1111/nep.12763.

PMID:
26990793
41.

Huntington's Disease as Neurodevelopmental Disorder: Altered Chromatin Regulation, Coding, and Non-Coding RNA Transcription.

Kerschbamer E, Biagioli M.

Front Neurosci. 2016 Jan 13;9:509. doi: 10.3389/fnins.2015.00509. eCollection 2015. No abstract available.

42.

ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer.

Jolly S, Soni P, Gaffney DK, Biagioli M, Elshaikh MA, Jhingran A, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Wahl AO, Williams NL, Yashar CM, Small W Jr.

Oncology (Williston Park). 2015 Nov;29(11):867-72, 874-5.

43.

American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer.

Stewart A, Parashar B, Patel M, O'Farrell D, Biagioli M, Devlin P, Mutyala S.

Brachytherapy. 2016 Jan-Feb;15(1):1-11. doi: 10.1016/j.brachy.2015.09.006. Epub 2015 Nov 7. Review.

PMID:
26561277
44.

Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice.

Bruscoli S, Biagioli M, Sorcini D, Frammartino T, Cimino M, Sportoletti P, Mazzon E, Bereshchenko O, Riccardi C.

Blood. 2015 Oct 8;126(15):1790-801. doi: 10.1182/blood-2015-03-631580. Epub 2015 Aug 14.

45.

Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes.

Yang G, Strom TJ, Wilder RB, Shrinath K, Mellon EA, Fernandez DC, Biagioli MC.

Int Braz J Urol. 2015 May-Jun;41(3):435-41. doi: 10.1590/S1677-5538.IBJU.2014.0289.

46.

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.

Contreras JA, Wilder RB, Mellon EA, Strom TJ, Fernandez DC, Biagioli MC.

Int Braz J Urol. 2015 Jan-Feb;41(1):40-5. doi: 10.1590/S1677-5538.IBJU.2015.01.07.

47.

A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

Schutzer ME, Orio PF, Biagioli MC, Asher DA, Lomas H, Moghanaki D.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):96-103. doi: 10.1038/pcan.2015.4. Epub 2015 Feb 17. Review.

PMID:
25687401
48.

Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation.

Biagioli M, Ferrari F, Mendenhall EM, Zhang Y, Erdin S, Vijayvargia R, Vallabh SM, Solomos N, Manavalan P, Ragavendran A, Ozsolak F, Lee JM, Talkowski ME, Gusella JF, Macdonald ME, Park PJ, Seong IS.

Hum Mol Genet. 2015 May 1;24(9):2442-57. doi: 10.1093/hmg/ddv006. Epub 2015 Jan 8.

49.

A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer.

Mellon EA, Javedan K, Strom TJ, Moros EG, Biagioli MC, Fernandez DC, Wasserman SG, Wilder RB.

Pract Radiat Oncol. 2015 Jan-Feb;5(1):11-5. doi: 10.1016/j.prro.2014.03.003. Epub 2014 Apr 18.

PMID:
25413432
50.

Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease.

Pryor WM, Biagioli M, Shahani N, Swarnkar S, Huang WC, Page DT, MacDonald ME, Subramaniam S.

Sci Signal. 2014 Oct 28;7(349):ra103. doi: 10.1126/scisignal.2005633.

PMID:
25351248

Supplemental Content

Loading ...
Support Center